(PM-26) Bibliometric study of the scientific production on extracorporeal shockwave therapy and erectile dysfunction

Abstract Aim To analyze the global scientific production on extracorporeal shockwave therapy (ESWT) for erectile dysfunction (ED). Methods. A bibliometric study was conducted using Scopus (search strategy keywords: “shockwave therapy” and “erectile dysfunction”), including all articles published up to May 4, 2025. The analysis focused on identifying the most relevant authors, main research affiliations, global scientific output by country, and the most cited journals in the field. For data processing and bibliometric analysis, OpenRefine 3.9.3 and the Bibliometrix package in R were used. Results. A total of 388 documents published (1999 to 2025; annual growth rate: 6.39%; 16.95 average citations per document) with 1454 unique authors (5.15 average co-authors per document) were identified. International collaboration was significant (20.62% of the publications). The USA was the leading contributor of correspondence author (75 documents), followed by Italy and China (both with 32). The most productive institutions were the Aristotle University of Thessaloniki (Greece) and the University of Miami (USA), both with 35 publications, followed by the University of California (USA; 30 publications). International collaboration was led by Belgium (50%), followed by Denmark (38.5%), and the United Kingdom (42.9%). The most cited document was Burnett AL et al. (2018; The Journal of Urology: 585 citations; 73.13 average citations per year), followed by Salonia A. et al. (2021; 523 citations, 104.60 average citations per year), and Vardi Y. (2010; 214 citations; 13.38 average citations per year), both articles were published in European Urology. The most prominent sources of publications were the International Journal of Impotence Research (46 documents), followed by the Journal of Sexual Medicine (21) and Translational Andrology and Urology (16). Conclusions Research into ESWT for ED shows sustained growth and significant global participation. Financing InSalud.